Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

3.8K
3.8K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

5.6K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.6K
Tumor Progression02:07

Tumor Progression

6.1K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical management of common toxicities with inhibitors targeting the PI3K/AKT/mTOR pathway in breast cancer.

ESMO open·2026
Same author

Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival.

ESMO open·2025
Same author

Long-term effect of neoadjuvant denosumab treatment in high-risk early breast cancer (GeparX).

ESMO open·2025
Same author

Long-term outcome data for patients with hormone receptor-positive early breast cancer participating in the WSG PlanB trial after preselection by gene expression analysis: 10-year survival results from the WSG PlanB registry.

ESMO open·2025
Same author

Integrative analysis of RNA expression signatures and recurrent genomic alterations before treatment: link to menopausal status, short-term endocrine therapy response and disease-free survival in luminal breast cancer.

ESMO open·2025
Same author

Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Related Experiment Video

Updated: Apr 22, 2026

Long-term Culture of Human Breast Cancer Specimens and Their Analysis Using Optical Projection Tomography
10:10

Long-term Culture of Human Breast Cancer Specimens and Their Analysis Using Optical Projection Tomography

Published on: July 29, 2011

18.4K

Breast Cancer 2012 - New Aspects.

H-C Kolberg1, D Lüftner2, M P Lux3

  • 1Klinik für Gynäkologie und Geburtshilfe, Marienhospital Bottrop, Bottrop.

Geburtshilfe Und Frauenheilkunde
|October 18, 2014
PubMed
Summary

Advances in breast cancer treatment integrate targeted therapies and pharmacogenomics, improving therapeutic decisions. Personalized medicine now combines tumor and patient genetic factors for optimal outcomes in primary and advanced breast cancer.

Keywords:
ABCSG-12BOLERO-2CLEOPATRAEMILIAGAINNSABP-B34TDM-1ZO-FASTeverolimuspertuzumab

More Related Videos

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial
03:07

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial

Published on: August 19, 2025

1.5K
Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies
09:01

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies

Published on: July 3, 2025

1.1K

Related Experiment Videos

Last Updated: Apr 22, 2026

Long-term Culture of Human Breast Cancer Specimens and Their Analysis Using Optical Projection Tomography
10:10

Long-term Culture of Human Breast Cancer Specimens and Their Analysis Using Optical Projection Tomography

Published on: July 29, 2011

18.4K
Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial
03:07

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial

Published on: August 19, 2025

1.5K
Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies
09:01

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies

Published on: July 3, 2025

1.1K

Area of Science:

  • Oncology
  • Pharmacogenomics
  • Translational Medicine

Background:

  • Breast cancer treatment options are expanding with new targeted therapies and chemotherapy combinations.
  • Therapeutic decisions increasingly incorporate tumor characteristics and patient's inherited genetic properties.
  • Health-economic aspects are becoming integral to treatment decision-making.

Purpose of the Study:

  • To review the latest advancements in primary and advanced breast cancer treatment.
  • To highlight the role of pharmacogenomics in personalizing therapy.
  • To discuss findings from major oncology congresses regarding novel therapeutic strategies.

Main Methods:

  • Review of recent scientific literature and presentations from major oncology conferences (San Antonio Breast Cancer Symposium 2011, ASCO Annual Meeting 2012).
  • Analysis of clinical trial data for metastatic and adjuvant breast cancer therapies.
  • Integration of information on clinical, molecular, and health-economic factors.

Main Results:

  • Clinically significant results from trials like CLEOPATRA, BOLERO-2, EMILIA, and SWOG S0226 for metastatic breast cancer.
  • State-of-the-art data on adjuvant bisphosphonate use from trials including ABCSG-12, ZO-FAST, NSABP-B34, and GAIN.
  • Emerging importance of pharmacogenomic biomarkers for prognostic and predictive value.

Conclusions:

  • Current breast cancer therapy relies on a combination of clinical and molecular biomarkers.
  • Personalized treatment strategies are evolving, considering both tumor and patient genetics.
  • Future treatment decisions will likely integrate efficacy, toxicity, and health-economic data for optimized patient care.